{"id":"NCT02751931","sponsor":"Astellas Pharma Europe B.V.","briefTitle":"Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity","officialTitle":"An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-17","primaryCompletion":"2018-11-05","completion":"2019-05-06","firstPosted":"2016-04-26","resultsPosted":"2020-05-12","lastUpdate":"2024-11-12"},"enrollment":91,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neurogenic Detrusor Overactivity"],"interventions":[{"type":"DRUG","name":"Mirabegron","otherNames":["YM178","Myrbetriq","Betanis","Betmiga"]}],"arms":[{"label":"Children (3 to < 12 Years)","type":"EXPERIMENTAL"},{"label":"Adolescents (12 to < 18 Years)","type":"EXPERIMENTAL"}],"summary":"The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.","primaryOutcome":{"measure":"Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 24","timeFrame":"Baseline and week 24","effectByArm":[{"arm":"Children (3 to < 12 Years)","deltaMin":72.09,"sd":87.09},{"arm":"Adolescents (12 to < 18 Years)","deltaMin":113.21,"sd":82.99}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG001","p":"<0.001"}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":32,"countries":["Australia","Belgium","Croatia","Denmark","Israel","Jordan","Latvia","Lithuania","Malaysia","Mexico","Norway","Philippines","Poland","Romania","Serbia","Slovakia","South Korea","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["34058027"],"seeAlso":["https://astellasclinicalstudyresults.com/patientStudySearch.aspx?RID=;;;178-CL-206A"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":55},"commonTop":["Escherichia urinary tract infection","Nasopharyngitis","Urinary tract infection bacterial","Constipation","Pyrexia"]}}